Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University), Ministry of Education, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.
Eur J Med Chem. 2013 Nov;69:77-89. doi: 10.1016/j.ejmech.2013.08.019. Epub 2013 Aug 19.
Two series of quinoline derivatives bearing the pyridine/pyrimidine scaffold were synthesized, and evaluated for their c-Met kinase inhibitory activity and antiproliferative activity against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) were evaluated in vitro. Most compounds showed moderate to excellent potency, and compared to foretinib, the most promising analog 18b (c-Met half-maximal inhibitory concentration [IC₅₀] = 1.39 nM) showed a 7.3-fold increase in activity against HT-29 cell line in vitro. Structure-activity relationship studies indicated that regulation of the electron density on the pyridine/pyrimidine ring to a proper degree was a key factor in improving the antitumor activity.
合成了两个含有吡啶/嘧啶支架的喹啉衍生物系列,并对它们的 c-Met 激酶抑制活性和对 5 种癌细胞系(HT-29、H460、MKN-45、A549 和 U87MG)的体外增殖活性进行了评估。大多数化合物表现出中等至优异的活性,与 Foretinib 相比,最有前途的类似物 18b(c-Met 半最大抑制浓度 [IC₅₀] = 1.39 nM)对 HT-29 细胞系的体外活性增加了 7.3 倍。构效关系研究表明,适当调节吡啶/嘧啶环上的电子密度是提高抗肿瘤活性的关键因素。